ARCUTIS BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.24 USD | +13.65% |
|
+15.64% | +186.07% |
| May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
| May. 15 | Sector Update: Health Care Stocks Rise Pre-Bell Wednesday | MT |
Presenter SpeechVikram Purohit (Analysts)Joining us. My name is Vikram Purohit. I'm one of the...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Companyâs pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
9.24
USD
Average target price
18.5
USD
Spread / Average Target
+100.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +186.07% | 939M | |
| +7.52% | 111B | |
| +11.38% | 106B | |
| -12.64% | 22.24B | |
| +0.44% | 21.25B | |
| -4.18% | 18.97B | |
| -37.85% | 18.52B | |
| -8.58% | 16.81B | |
| +37.41% | 12.54B | |
| -23.95% | 8.09B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Transcript : Arcutis Biotherapeutics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 08
